Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ACTRIMS-ECTRIMS 2026

ACTRIMS-ECTRIMS Meeting (MSToronto2026)

October 21–23, 2026

  1. All
  2. NMOSD

HTML

Sato W et al. A real-world study of the effectiveness and safety of ravulizumab in AQP4-Ab+ NMOSD patients with suboptimal response to satralizumab in Japan (Abstract)

HTML

O’Hayer C et al. ACT with NMOSD: a caregiver-assisted targeted mental health intervention (Abstract)

HTML

Okuda D et al. Clinical and radiological outcomes in people with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE) (Abstract)

HTML

Müller-Jensen L et al. Early and sustained immune dysregulation precedes seroconversion and CNS injury in NMOSD (Abstract)

PDF

Osborne B et al. Factors associated with a switch from rituximab to approved treatments among patients with neuromyelitis optica spectrum disorder in the United States (Poster)

PDF

Nakahara J et al. First analysis of the safety, effectiveness, and corticosteroid-sparing effects of ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: real-world data from Japan (Poster)

PDF

Sotirchos E et al. NMO SPOTLIGHT Registry: real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) (Poster)

HTML

Rotstein D et al. Optimizing the management of AQP4-IgG+ NMOSD: a Canadian consensus (Abstract)

HTML

Genecov M et al. SMART NMO: A tool to measure the mental health burden of neuromyelitis optica spectrum disorder (Abstract)

HTML

Levy M et al. The OPTIS study for clinical validation of NMOSD Copilot, a software as a medical device for remote monitoring of NMOSD manifestations (Abstract)

HTML

Sato W et al. A real-world study of the effectiveness and safety of ravulizumab in AQP4-Ab+ NMOSD patients with suboptimal response to satralizumab in Japan (Abstract)

HTML

O’Hayer C et al. ACT with NMOSD: a caregiver-assisted targeted mental health intervention (Abstract)

HTML

Okuda D et al. Clinical and radiological outcomes in people with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE) (Abstract)

HTML

Müller-Jensen L et al. Early and sustained immune dysregulation precedes seroconversion and CNS injury in NMOSD (Abstract)

PDF

Osborne B et al. Factors associated with a switch from rituximab to approved treatments among patients with neuromyelitis optica spectrum disorder in the United States (Poster)

PDF

Nakahara J et al. First analysis of the safety, effectiveness, and corticosteroid-sparing effects of ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: real-world data from Japan (Poster)

PDF

Sotirchos E et al. NMO SPOTLIGHT Registry: real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) (Poster)

HTML

Rotstein D et al. Optimizing the management of AQP4-IgG+ NMOSD: a Canadian consensus (Abstract)

HTML

Genecov M et al. SMART NMO: A tool to measure the mental health burden of neuromyelitis optica spectrum disorder (Abstract)

HTML

Levy M et al. The OPTIS study for clinical validation of NMOSD Copilot, a software as a medical device for remote monitoring of NMOSD manifestations (Abstract)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States